In Vitro: TP-1287 suppresses MCL-1 expression via CDK9-mediated regulation of RNA polymerase II.
In Vivo: TP-1287 (2.5-15 mg/kg; oral) suppresses tumor growth in models of multiple myeloma. TP-1287 is highly soluble over a broader pH range than Alvocidib (HY-10005) and is efficiently metabolized to the parent compound in vivo, following oral administration.